Model No.: 10%
Oxytetracycline Injection is intended for use in the treatment of the following diseases in beef cattle, nonlactating dairy cattle and swine when due to oxytetracycline susceptible organisms.
Oxytetracycline 200 is indicated in the treatment of pneumonia and shipping fever complex associated with Pasteurella spp. and Hemophilus spp.; infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis; foot rot and diphtheria caused by Fusobacterium necrophorum; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresi; leptospirosis caused by Leptospira pomona; and wound infections and acute metritis caused by strains of staphylococci and streptococci organisms sensitive to oxytetracycline.
In swine, Oxytetracycline 200 is indicated in the treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli; pneumonia caused by Pasteurella multocida; and leptospirosis caused by Leptospira pomona.
In sows, Oxytetracycline 200 is indicated as an aid in the control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.
If you are a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.If you are a consumer, don't hesitate to contact us about more information for this product.
NOUVASANT PHARMhealth LTD.
NOUVASANT is headquartered in Nanjing city, located in the lower reaches of the Yangtze River, one of the six ancient capitals of China. NOUVASANT is composed of research, development, production and sales. All the production workshops have passed the national GMP certification, and the production process is in strict accordance with the GMP requirements.
Products cover: antipyretic analgesic, antibiotic series, respiratory drugs, nervous system drugs, cardiovascular drugs, digestive system drugs, anti-malarial drugs, anti-cancer drugs, covering pharmaceutical API and Preparations.
Core Value: In Search of Excellence
Mission: devoted to providing safe, effective, high-quality and humanized products to Humankind.
- Company Name: NOUVASANT PHARMhealth LTD.
- Product/Service: Finished Pharmaceutical Product , API & Raw materials , Medical Items , Antibiotic & Antimicrobial , Medical Disposables , Antifungal Drugs
- Capital (Million US $): 21,000,000RMB
- Year Established: 2010
- Total Annual Sales Volume (Million US $): US$10 Million - US$50 Million
- Export Percentage: 71% - 80%
- Total Annual Purchase Volume (Million US $): US$10 Million - US$50 Million
- No. of Production Lines: Above 20
- No. of R&D Staff: 21 -30 People
- No. of QC Staff: 11 -20 People
- OEM Services Provided: yes
- Factory Size (Sq.meters): 30,000-50,000 square meters
- Factory Location: 2110 Zifeng Tower, No.1 North Zhongshan Road, Gulou, Nanjing, 210009, China
- Contact Person: Mr. Andy
- Tel: 86-025-58771602
Premium Related Products